Impact of concomitant idiopathic pulmonary fibrosis on prognosis in lung cancer patients: A meta-analysis

Abstract

Background Current studies showed that idiopathic pulmonary fibrosis (IPF) may lead to a poor prognosis of lung cancer. We conducted a meta-analysis to explore the impact of concomitant IPF in lung cancer and its prognostic value. Methods We searched the databases of PubMed, Web of Science, Embase up to Feb 10th, 2021 for relevant researches and merged the hazard ratios (HRs) and 95% confidence intervals (CIs) to evaluate the association between concomitant IPF and overall survival (OS) in patients with lung cancer. Results Twelve studies involving 58424 patients were included in our meta-analysis. The results indicated that concomitant IPF was correlated with poor prognosis of lung cancer patients (HR = 1.99, 95%CI, 1.59–2.51). The association remained consistent after subgroup analysis and meta-regression stratified by study region, sample size, tumor histology, and therapy. In addition, our results were robust even after sensitivity analysis. Conclusions Concomitant IPF may be a prognostic factor of lung cancer, which can lead to poor survival. However, further studies were necessary for evidence in clinical application.

Risk of second primary lung cancer in patients with thyroid cancer: a meta-analysis based on big population studies

“…Radiotherapy often results in pulmonary injuries in clinical practice, which is called radiation-induced lung injury (RILI) and is especially observed during tumor treatment [46] . Radiation-induced pulmonary or systemic inflammation and malnutrition may lead to the appearance and development of lung cancer, [47,48] whereas pulmonary fibrosis, the most severe form of RILI, also increases the risk and worsens the prognosis of lung cancer because of a decline in lung function and activation of some tumor-associated pathways [49,50] . In addition, radiation itself can also induce novel genomic alterations irrespective of the type of primary tumor, suggesting that the genetic impact could be another contributing factor [51] …”

Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study

“…In 2022, the research definition and classification criteria of CPFE as a clinical syndrome were formalized in an official statement by the American Thoracic Society (ATS), the European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and the Latin American Thorax Association (ALAT) [15]. Epidemiological studies uncovered the association of lung cancer risk and IPF [16][17][18], and IPF seems to increase the risk of death in patients with lung cancer [19,20]. An association of lung cancer and idiopathic CPFE has also been suggested.…”